Nexxus Iberia announces the seventh investment of Nexxus Iberia Private Equity Fund I, FCR. by the acquisition of a controlling stake in Mercurius Health and a package of financing to support its international expansion

Nexxus Iberia announces the seventh investment of Nexxus Iberia Private Equity Fund I, FCR. by the acquisition of a controlling stake in Mercurius Health and a package of financing to support its international expansion

Nexxus Iberia announces that Nexxus Iberia Private Equity Fund I, FCR (the “Fund”) has completed its seventh investment by acquiring Mercurius Health (“Mercurius” or “the Company”) on August 7th, 2020.

Founded in 1998, the Company is a specialized B2B provider of radiotherapy and nuclear medicine services to oncology clinics and hospitals in both the private and public sectors, where it is focused on delivering consultancy services, technical cooperation, operations support and training to its partners. As the market leader in Portugal, Mercurius currently supports almost 60% of Portugal’s private provision of radiotherapy services and employs over 100 radiotherapy and nuclear medicine specialists, making it one of the largest independent networks in Europe. The Company is based in Lisbon, has operations in Portugal and Africa and works throughout Europe in providing its services to a wide base of radiation oncology clients.

Nexxus Iberia believes that Mercurius is well positioned to benefit from the growth expected in the radiation oncology industry. Given the increasing use of radiotherapy in providing cancer treatments, the rapid development of new technology in the sector and the shortage of skilled professionals needed to implement such technology in the clinical environment, it is expected that these factors will drive investment and demand for Mercurius’s specialised services.

Nexxus co-invests with a group of professionals with extensive clinical and managerial experience in the industry who will lead the project, complement Mercurius’ service offering and accelerate its international expansion.

Maite Ballester, partner at Nexxus Iberia explained: “Mercurius Health has all the elements of the sort of growth project we look to invest in. The Company is the market leader in Portugal with a proven and solid business model which can be replicated in many other countries to support oncology providers of care to offer radiotherapy where previously this was not possible.

Alejandro Diazayas, partner at Nexxus Iberia explained: “Mercurius Health operates in a non-cyclical industry with strong fundamentals. The management team of Mercurius Health has the background and experience to lead the execution of our expansion plan. We are confident the company will be transformed into a European leader in its field within our holding period”.

John Allen, board Member of Mercurius explained: “We are excited to have partnered with Nexxus Iberia for this project. It not only secures us the funding required to execute an aggressive growth strategy but will also allow us to promote new state of the art clinical services and data management to our partners so that they can provide outstanding radiotherapy services to their patients. Nexxus’ team industry knowledge and experience in internationalization of companies will be key assets for the success of our project”.

Nexxus Iberia was advised in the transaction by Cuatrecasas and Abreu Advogados (legal), PwC (Due Diligence) and Attalea Partners (ESG).